Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Diazoxide
10 evidence topics · 11 sources
First-line medical therapy for advanced insulinoma: ENETS guidance
Diazoxide in metastatic insulinoma: ESMO guideline
Preoperative control of insulinoma hypoglycemia with diazoxide: NANETS surgical guideline
Dosing and adverse effects of diazoxide in insulinoma: clinical review
“Diazoxide is a nondiuretic benzothiadiazide vasodilator also known to control insulin secretion by blocking the adenosine triphosphate-dependent potassium channels of the pancreatic β cells (75).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Generally, doses between 300 and 900 mg per day, usually divided into 3 equal and increasing doses every 8 hours, are rapidly successful in reversing hypoglycemia. The most frequent dose-limiting side effects of diazoxide occurring in up to 80% are fluid retention and edema, palpitations, nausea, anorexia, and hirsutism in female patients. Combination with a thiazide diuretic is generally recommended to prevent fluid retention, edema, and severe weight gain (7, 70, 78–80).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indication, dosing, warnings, and adverse reactions: diazoxide prescribing information
Long-term diazoxide in 40 patients with insulinoma: national survey
“A survey of UK patients receiving the drug diazoxide, revealed 40 patients with insulinoma on this treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Duration of treatment was 7 +/- 6 years (range 1-22). Most (55%) patients were treated with diazoxide because of tumour non-localisation (including failed previous surgery). Metastatic disease (20%) and poor surgical risk (10%) were other indications. Side-effects (notably fluid retention and hirsutism) were common (47%) but not troublesome. Treatment was highly effective--59% were symptom free and 38% had only occasional symptoms. Only one patient had frequent hypoglycaemia despite treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide response and adverse effects in 20 patients with insulinoma
“We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Edema and heart failure with diazoxide in inoperable insulinoma
“Herein, we report the results of our retrospective clinical record review of 6 Japanese patients (3 females and 3 males, ranging in age from 58 to 91 years) with hyperinsulinemic hypoglycemia and inoperable insulinoma treated with diazoxide. Diazoxide improved control of hypoglycemic symptoms and maintained normoglycemia in 5 of the 6 patients, and was ineffective in one patient. Surprisingly, although all 6 patients received diazoxide according to the treatment strategy recommended in Western patients, 5 of the 6 patients developed edema and two developed congestive heart failure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide in NICTH: clinical review
“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use in NICTH was not found to be successful in any case we reviewed (33, 36, 41, 53, 90). Additionally, use is often limited by fluid retention and edema (41).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide among recovered and deceased patients with IGF-2-mediated NICTH
| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
|---|---|---|---|---|
| Diazoxide | “16 (6.9%)”View highlighted excerpt for this quote | “10 (5.8%)”View highlighted excerpt for this quote | “6 (11.8%)”View highlighted excerpt for this quote | “.25”View highlighted excerpt for this quote |